Stock Comparison

MDGL vs REGN

Madrigal Pharmaceuticals Inc and Regeneron Pharmaceuticals Inc side by side — valuation, profitability, growth and risk.

MDGL

Madrigal Pharmaceuticals Inc

Healthcare

REGN

Regeneron Pharmaceuticals Inc

Healthcare

Valuation

Market Cap

$11.60B

$80.55B

P/E (TTM)

—

19.4

Forward P/E

656.4

17.1

Price/Sales

9.0

5.2

Price/Book

22.1

2.5

EV/EBITDA

-8.2

13.1

Dividend Yield

—

0.45%

Profitability

Net Margin

-27.32%

29.65%

Operating Margin

-27.68%

24.32%

Return on Equity

-53.30%

14.00%

Return on Assets

-17.80%

6.53%

Growth (YoY)

Revenue Growth

71.20%

16.70%

Earnings Growth

0.00%

-4.50%

Price & Risk

Beta

-1.0

0.2

52-Week High

$602.83

$810.12

52-Week Low

$369.84

$553.38

Analyst Target

$678.06

$833.54

Compare MDGL and REGN your own way

Try mrmarket.ai free

Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.